52-01-7
52-01-7 structure
- Name: Spironolactone
- Chemical Name: Spironolactone
- CAS Number: 52-01-7
- Molecular Formula: C24H32O4S
- Molecular Weight: 416.573
- Catalog: API Urinary system medication Diuretic
- Create Date: 2018-02-06 08:00:00
- Modify Date: 2026-07-04 07:41:35
-
Spironolactone is a potent antagonist of the androgen receptor. Target: Androgen ReceptorSpironolactone is a potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. 5% topical spironolactone cream acts as an antiandrogen in human sebaceous glands, competing with DHT receptors and producing a decrease of labelled DHT. At the concentrations used the effect has been only local. No side-effects were recorded during both studies [1]. Patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients [2].
| Name | Spironolactone |
|---|---|
| Synonyms |
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-cbolactone
3-(3-Keto-7alpha-acetylthio-17beta-hydroxy-4-androsten-17alpha-yl)propionic acid lactone Sagisal Laractone Suracton Diatensec spironolactone Aqueduct Deverol Verospirone Opianin Aquareduct Lacalmin Euteberol 17-HYDROXY-7-ALPHA-MERCAPTO-3-OXO-17-ALPHA-PREGU-4-ENE-2[CBOXYLIC ACID-GAMMA-LACTONE-7-ACETATE] Ethanethioic acid, S-[(7R,8R,9S,10R,13S,14S,17R)-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-10,13-dimethyl-3,5'-dioxospiro[17H-cyclopenta[a]phenanthrene-17,2'(3'H)-furan]-7-yl] ester 3-(3-keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propion Nefurofan icacidlactone Duraspiron 3'-(3-Oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propionic acid lactone 17-hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-cboxylic acid-gamma-lactone-7-acetate Abbolactone Urusonin 17-alpha-Pregn-4-ene-21-cboxylic acid, 1-hydroxy-7-alpha-mercapto-3-oxo-alpha-lactone VEROSPIRON SPIRONOLACTONE A a-lactone,acetate 17-hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-cboxylicacigamm 7ALPHA-[ACETYLTHIO]-17ALPHA-HYDROXY-3-OXOPREGN-4-ENE-21-CBOXYLIC ACID GAMMA-LACTONE Aldactone Spiroderm Spiretic SpironolaCLone Alderon Dira SPIRONOLACTONE Altex Spirolone Almatol (7alpha,17alpha) 4-PREGNEN-21-OIC ACID-17ALPHA-OL-3-ONE-7ALPHA-THIOL GAMMA-LACTONE 7-ACETATE Spirolakton Aldopur Osiren 17-alpha-pregn-4-ene-21-cboxylicacid,1-hydroxy-7-alpha-mercapto-3-oxo-alpha acidlactone Sprioderm Spironolactone for system suitability Spironolac Aldactone A MFCD00082250 3-(3-keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic Acelat S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate Supra-puren 4,17ALPHA-PREGNEN-21-CBOXYLIC ACID-17BETA-OL-3-ONE-7ALPHA-THIOL GAMMA LACTONE 7-ACETATE 7-(acetylthio)-17-hydroxy-3-oxo-pregn-4-ene-21-cboxylicacigamma-lactone 3’-(3-oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propioni Pregn-4-ene-21-cboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, γ-lactone, (7α,17α) Aldace (7a,17a)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid g-lactone EINECS 200-133-6 Verospirone Osyrol 7-alpha-Acetylthio-3-oxo-17-beta-pregn-4-ene-21,17-beta-cbolactone Lacdene Uractone Lactone Aldactide ALDACTONE 17alpha-Pregn-4-ene-21-cboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate Xenalon 17-hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-cboxylicaciga 17-Hydroxy-7a-mercapto-3-oxo-17a-pregn-4-ene-21-carboxylic Acid g-Lactone Acetate S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-Dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate cacidlactone 3-(3-Oxo-7a-acetylthio-17b-hydroxy-4-androsten-17a-yl)propionic Acid g-Lactone 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-cboxylic acid gamma-lactone acetate Sincomen aldactonea |
| Description | Spironolactone is a potent antagonist of the androgen receptor. Target: Androgen ReceptorSpironolactone is a potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. 5% topical spironolactone cream acts as an antiandrogen in human sebaceous glands, competing with DHT receptors and producing a decrease of labelled DHT. At the concentrations used the effect has been only local. No side-effects were recorded during both studies [1]. Patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 597.0±50.0 °C at 760 mmHg |
| Melting Point | 207-208 °C(lit.) |
| Molecular Formula | C24H32O4S |
| Molecular Weight | 416.573 |
| Flash Point | 302.3±18.1 °C |
| Exact Mass | 416.202118 |
| PSA | 85.74000 |
| LogP | 3.12 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.586 |
| Water Solubility | practically insoluble |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360 |
| Precautionary Statements | P201-P280-P308 + P313 |
| Personal Protective Equipment | Eyeshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic |
| Risk Phrases | R40;R60 |
| Safety Phrases | 53-22-36/37/39-45-36-26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | TU4725000 |
| HS Code | 2937290090 |
|
~63%
52-01-7 |
| Literature: Wuts, Peter G. M.; Ritter, Allen R. Journal of Organic Chemistry, 1989 , vol. 54, # 21 p. 5180 - 5182 |
|
~%
52-01-7 |
| Literature: Cella; Tweit Journal of Organic Chemistry, 1959 , vol. 24, p. 1109 |
|
~%
52-01-7 |
| Literature: Wuts, Peter G. M.; Ritter, Allen R. Journal of Organic Chemistry, 1989 , vol. 54, # 21 p. 5180 - 5182 |
|
~%
52-01-7 |
| Literature: Wuts, Peter G. M.; Ritter, Allen R. Journal of Organic Chemistry, 1989 , vol. 54, # 21 p. 5180 - 5182 |
|
~%
52-01-7 |
| Literature: Wuts, Peter G. M.; Ritter, Allen R. Journal of Organic Chemistry, 1989 , vol. 54, # 21 p. 5180 - 5182 |
|
~%
52-01-7 |
| Literature: Wuts, Peter G. M.; Ritter, Allen R. Journal of Organic Chemistry, 1989 , vol. 54, # 21 p. 5180 - 5182 |
|
~%
52-01-7 |
| Literature: Marjani, Katayoun; Khalesi, Maryam; Ashouri, Akram; Jalali, Aazam; Ziyaei-Halimehjani, Azim Synthetic Communications, 2011 , vol. 41, # 3 p. 451 - 458 |
|
~%
52-01-7 |
| Literature: Cella; Tweit Journal of Organic Chemistry, 1959 , vol. 24, p. 1109 |
| Precursor 5 | |
|---|---|
| DownStream 3 | |
| HS Code | 2937290090 |
|---|